CN113795268B - 治疗眼疾的方法 - Google Patents

治疗眼疾的方法 Download PDF

Info

Publication number
CN113795268B
CN113795268B CN202080025566.3A CN202080025566A CN113795268B CN 113795268 B CN113795268 B CN 113795268B CN 202080025566 A CN202080025566 A CN 202080025566A CN 113795268 B CN113795268 B CN 113795268B
Authority
CN
China
Prior art keywords
diabetic retinopathy
eye
thickness
administration
beauvericin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080025566.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN113795268A (zh
Inventor
李水盛
苏铭嘉
林隆志
徐兆民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zih Yuan Tang Biotechnology Co ltd
Original Assignee
Zih Yuan Tang Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zih Yuan Tang Biotechnology Co ltd filed Critical Zih Yuan Tang Biotechnology Co ltd
Publication of CN113795268A publication Critical patent/CN113795268A/zh
Application granted granted Critical
Publication of CN113795268B publication Critical patent/CN113795268B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15Depsipeptides; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080025566.3A 2019-04-03 2020-04-01 治疗眼疾的方法 Active CN113795268B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962828616P 2019-04-03 2019-04-03
US62/828,616 2019-04-03
US201962899279P 2019-09-12 2019-09-12
US62/899,279 2019-09-12
PCT/CN2020/082765 WO2020200241A1 (en) 2019-04-03 2020-04-01 Method for treating ocular diseases

Publications (2)

Publication Number Publication Date
CN113795268A CN113795268A (zh) 2021-12-14
CN113795268B true CN113795268B (zh) 2025-04-08

Family

ID=72662774

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080025566.3A Active CN113795268B (zh) 2019-04-03 2020-04-01 治疗眼疾的方法

Country Status (8)

Country Link
US (1) US11033603B2 (https=)
EP (1) EP3946414B1 (https=)
JP (1) JP7461663B2 (https=)
KR (1) KR20210149087A (https=)
CN (1) CN113795268B (https=)
SG (1) SG11202110659SA (https=)
TW (1) TWI818168B (https=)
WO (1) WO2020200241A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI788083B (zh) * 2021-11-03 2022-12-21 葡萄王生技股份有限公司 蟬花菌絲體活性物質用於治療黃斑部病變之用途
CN120936366A (zh) * 2023-03-20 2025-11-11 资元堂生物科技股份有限公司 一种白殭菌素用于制备抑制血管新生药物的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0327316A (ja) * 1989-06-23 1991-02-05 Kitasato Inst:The 高脂血症治療剤
KR20080031474A (ko) * 2005-07-27 2008-04-08 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 안구 질환의 치료를 위한 열충격의 사용
CN101669939A (zh) * 2009-09-22 2010-03-17 中山大学 恩镰孢菌素类化合物在制备抗耐药结核菌药物中的应用
US20140275091A1 (en) * 2013-03-15 2014-09-18 Coyote Pharmaceuticals, Inc. Ocular formulations comprising geranylgeranylacetone derivatives for intraocular delivery
US20140371158A1 (en) * 2013-06-14 2014-12-18 Georgia Regents University Beauvericin compositions and methods thereof for inhibiting the hsp90 chaperone pathway
CN109200066A (zh) * 2017-07-07 2019-01-15 葡萄王生技股份有限公司 蝉花活性物质及其用于预防、延缓或治疗白内障的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
白僵菌素对支气管哮喘模型小鼠气道炎症的影响及其机理研究;吴刚;朱佳;朱际平;;江苏中医药;20170605(第06期);摘要 *

Also Published As

Publication number Publication date
EP3946414A4 (en) 2022-12-07
US20200316165A1 (en) 2020-10-08
JP7461663B2 (ja) 2024-04-04
KR20210149087A (ko) 2021-12-08
JP2022528566A (ja) 2022-06-14
WO2020200241A1 (en) 2020-10-08
TW202102252A (zh) 2021-01-16
EP3946414A1 (en) 2022-02-09
EP3946414B1 (en) 2025-12-03
CA3132137A1 (en) 2020-10-08
EP3946414C0 (en) 2025-12-03
CN113795268A (zh) 2021-12-14
US11033603B2 (en) 2021-06-15
TWI818168B (zh) 2023-10-11
SG11202110659SA (en) 2021-10-28

Similar Documents

Publication Publication Date Title
Massin et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial
Audren et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg
Miyake Prevention of cystoid macular edema after lens extraction by topical indomethacin (I) A preliminary report
US8097640B2 (en) Prophylactic or therapeutic agent for diabetic maculopathy
Suto et al. A novel dual agonist of EP3 and FP receptors for OAG and OHT: safety, pharmacokinetics, and pharmacodynamics of ONO-9054 in healthy volunteers
CN113795268B (zh) 治疗眼疾的方法
KOLLARITS et al. Norepinephrine therapy of ischemic optic neuropathy
CA3132137C (en) Method for treating ocular diseases
JP4578593B2 (ja) 糖尿病性網膜症治療のためのスロデキサイドを含有する医薬
Shin et al. Intraocular Pressure-denpendent Retinal Vascular Change in Adult Chronic Open-angle Glaucoma Patients
Ozdemir et al. Comparison of the intraocular pressure lowering effect of latanoprost and carteolol-pilocarpine combination in newly diagnosed glaucoma
Mehra et al. Occurrence of cystoid macular edema after uneventful phacoemulsification in diabetic patients without retinopathy: a hospital-based comparative study
Schilling et al. An elusive case of cystoid macular edema
Rolando et al. Cyclosporine pharmacokinetics in healthy volunteers after ocular administration of OTX-101, a novel nanomicellar cyclosporine formulation
EP3331517B1 (fr) Utilisation d'hydroxycarbamide pour prevenir la non-perfusion retinienne
WO2024090606A1 (ko) 후공막염의 치료방법
Nowak et al. Protective effect on visual functions of long-term use of trimetazidine in treatment of primary open angle glaucoma and degenerative myopia
RU2356520C1 (ru) Способ лечения постконтузионного повреждения сетчатки глаза
Farag et al. Study of Structural Changes in Diabetic Macular Edema by Spectral Domain Optical Coherent Tomography after Intravitreal Injection of Triamcinolone Acetonide
Rhee et al. The effects of Bendaline (R) on cataracts.
Cameron et al. DIABETIC RETINOPATHY AND CYANCOBALAMIN (VITAMIN B12): A PRELIMINARY REPORT
Sanabria et al. Atypical myopic retinoschisis
Obiudu et al. Central Retinal Vein Occlusion AssociatedWith Sildenafil (Viagra)
JP2021134176A (ja) ムーコル症治療薬
Upadhyay et al. Efficiency of Fenofibrate in Facilitating the Reduction of Central Macular Thickness in Diabetic Macular Edema

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant